Jessica Tassan analyst PIPER SANDLER

Currently out of the existing stock ratings of Jessica Tassan, 40 are a HOLD (20.51%), 2 are a SELL (1.03%), 153 are a BUY (78.46%).

Jessica Tassan

Work Performance Price Targets & Ratings Chart

Analyst Jessica Tassan, currently employed at PIPER SANDLER, has had 53.5% of price targets met with an average potential upside of 21.07%, reached in 125 days on average.

Jessica Tassan has documented 384 price targets and ratings displayed on 28 stocks. The coverage is on Healthcare, Technology sectors.

Most recent stock forecast was given on CI, Cigna Corp at 11-Nov-2026.

Wall Street Analyst Jessica Tassan

Analyst best performing recommendations are on NXGN.
The best stock recommendation documented was for HCAT (HEALTH CATALYST) on 9/13/2022. The price target of $11 was fulfilled within 1 day with a profit of $0.28 (2.61%), with a performance score of 26.12.

Average potential price target upside

CANO CMAX HCAT Health Catalyst SGFY TRHC CHNG Change Healthcare EVH Evolent Health OMCL Omnicell OSH PHR Phreesia TDOC ALHC PRVA Privia Health Group AMWL DOCS MDRX ACCD CVS CVS Health Corp NXGN PINC UNH UnitedHealth Group MPLN CI Cigna Corp HUM Humana OSCR Oscar Health BNFT Benefitfocus CM ONEM

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Sell

$12

3 years 3 days ago
(17-Nov-2023)

0/1 (0%)

$4.37 (57.27%)

Hold

$0.5

$2.5

3 years 3 months 6 days ago
(14-Aug-2023)

0/5 (0%)

$3.12 (70.54%)

Buy

$0.8

$12

3 years 3 months 9 days ago
(11-Aug-2023)

0/3 (0%)

$3.48 (64.74%)

Buy

$17

3 years 3 months 9 days ago
(11-Aug-2023)

0/1 (0%)

$4.88 (40.26%)

Buy

3 years 7 months 17 days ago
(03-Apr-2023)

4/4 (100%)

$2.26 (47.68%)

338

Show more analysts

Please expand the browser size to see the chart

Which stock is Jessica Tassan most bullish on?

Potential upside of $140.22 has been obtained for HUM (HUMANA)

Which stock is Jessica Tassan most reserved on?

Potential downside of $9.97 has been obtained for OMCL (OMNICELL)

What Year was the first public recommendation made by Jessica Tassan?

On 2016
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?